Remed Co.Ltd (KQ:302550) — Market Cap & Net Worth
Market Cap & Net Worth: Remed Co.Ltd (302550)
Remed Co.Ltd (KQ:302550) has a market capitalization of $53.86 Million (₩79.47 Billion) as of September 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21729 globally and #1306 in its home market, demonstrating a -2.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Remed Co.Ltd's stock price ₩2625.00 by its total outstanding shares 30275013 (30.28 Million). Also see Remed Co.Ltd assets under control for a full breakdown of the balance sheet.
Remed Co.Ltd Market Cap History: 2019 to 2026
Remed Co.Ltd's market capitalization history from 2019 to 2026. Data shows growth from $2.17 Million to $53.86 Million (60.08% CAGR). Also see Remed Co.Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Remed Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$235.78 Billion | 0.02% | #608 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$235.78 Billion | 0.02% | #608 of 1384 |
Weight: Remed Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Remed Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Remed Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 302550 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Remed Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.12x
Remed Co.Ltd's market cap is 0.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.17 Million | $18.55 Billion | $4.36 Billion | 0.00x | 0.00x |
| 2020 | $5.37 Million | $16.63 Billion | -$1.83 Billion | 0.00x | N/A |
| 2021 | $4.36 Million | $20.20 Billion | $752.33 Million | 0.00x | 0.01x |
| 2022 | $2.03 Million | $21.36 Billion | $4.00 Billion | 0.00x | 0.00x |
| 2023 | $66.78 Million | $18.54 Billion | $797.17 Million | 0.00x | 0.08x |
| 2024 | $73.86 Million | $25.55 Billion | $7.17 Billion | 0.00x | 0.01x |
| 2025 | $62.99 Million | $24.50 Billion | $526.20 Million | 0.00x | 0.12x |
Competitor Companies of 302550 by Market Capitalization
Companies near Remed Co.Ltd in the global market cap rankings as of September 19, 2026. Review Remed Co.Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Remed Co.Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Remed Co.Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Remed Co.Ltd's market cap moved from $2.17 Million to $ 53.86 Million, with a yearly change of 60.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩53.86 Million | -14.50% |
| 2025 | ₩62.99 Million | -14.72% |
| 2024 | ₩73.86 Million | +10.60% |
| 2023 | ₩66.78 Million | +3194.53% |
| 2022 | ₩2.03 Million | -53.48% |
| 2021 | ₩4.36 Million | -18.81% |
| 2020 | ₩5.37 Million | +147.73% |
| 2019 | ₩2.17 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Remed Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.86 Million USD |
| MoneyControl | $53.86 Million USD |
| MarketWatch | $53.86 Million USD |
| marketcap.company | $53.86 Million USD |
| Reuters | $53.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more